There were approximately 17-18 million new cancer cases diagnosed worldwide in 2018, of which about 7% – or 1.2 million people – were blood cancers. While tremendous progress in the treatment of these cancers has been made and survival rates for common blood cancers have consistently improved over time, there is still work to be done. Certain blood cancers, like acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), can be more difficult to treat because they are rare and have a more aggressive nature.
Every three minutes, someone in the U.S. is diagnosed with a blood cancer. Fast-growing blood cancers like acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) can become life-threatening if left untreated because they can quickly spread to other parts of the body, including the brain and spinal cord. Hematopoietic stem cell transplantation (HSCT) can provide an important option in improving outcomes for appropriate patients.
VOD, also known as sinusoidal obstruction syndrome, begins in the liver and can quickly affect other vital organs, most notably the kidneys and lungs. It is a rare and potentially deadly complication of hematopoietic stem cell transplantation (HSCT) occurring in approximately 9-14% of HSCT patients.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.